Andrea Herencia-Ropero

Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial

Alba Llop‐Guevara, Sibylle Loibl, Guillermo Villacampa et al. · Annals of Oncology · 2021 · 101 citations · Full text

Life Sciences, Genetics, Oncology +10

Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

Benedetta Pellegrino, Andrea Herencia-Ropero, Alba Llop‐Guevara et al. · Cancer Research · 2022 · 97 citations · Full text

Medicine, Genetics, Oncology +15

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

Violeta Serra, Anderson T. Wang, Marta Castroviejo‐Bermejo et al. · Clinical Cancer Research · 2022 · 85 citations · Full text

Life Sciences, Cancer Biology, Oncology +17

The Expansion of Inosine at the Wobble Position of tRNAs, and Its Role in the Evolution of Proteomes

Àlbert Rafels-Ybern, Adrián Gabriel Torres, Noelia Camacho et al. · Molecular Biology and Evolution · 2018 · 77 citations

Life Sciences, Evolutionary Biology, Molecular Biology +9

RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer

Amanda J. Compadre, Lillian N. van Biljon, Mark C. Valentine et al. · Clinical Cancer Research · 2023 · 65 citations · Full text

Medicine, Gynecology, Oncology +16